An AI-powered biomarker based on histology alone predicted survival among men with metastatic hormone-sensitive prostate cancer and identified those who benefitted from escalation to triplet therapy.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

SAN FRANCISCO -- Prophylactic whole-pelvic radiation therapy (RT) did not perform as expected for patients with unfavorable intermediate-risk or favorable high-risk prostate cancer, according to ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

New technologies can potentially save lives by helping identify prostate cancer earlier, and transforming the way doctors ...

Older men with prostate cancer who receive federal housing assistance at the time they are first diagnosed have better two-year survival chances compared to demographically and clinically similar men ...

Prostate cancer incidence is increasing, especially in advanced stages, reversing previous declines and slowing mortality rate improvements. Racial disparities persist, with Black and Native American ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over 12,000 men in Sweden.

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...